Introducing Prime's Year-3 GLP-1 real-world data

Prime Therapeutics (Prime) is excited to share findings from our Year-3 research into glucagon-like peptide-1 (GLP-1) weight loss therapy. The press release features key findings of Prime’s continued research into real-world use of GLP-1 drugs for weight loss and will present adherence/persistence data for individuals who have continued therapy for three years. 

This is a continuation of Prime’s industry-leading data and research on GLP-1 weight loss therapy. Highlights from this year's release include:

• Long-term persistence remains low
  Only eight percent of individuals without diabetes initiating a GLP-1 agonist for obesity continued to do so at three years.
• Short-term persistence improved
  While overall persistence continues to decrease among those taking obesity treatment high-potency GLP-1s after three years, persistence among individuals taking the drugs over a one-year period improved dramatically for those starting therapy in Q1 2024 compared to prior years.
• High switching rate
  Thirty-eight percent of individuals switched GLP-1 products during the study.

Prime's approach

We take an evidence-based approach to GLP-1 medications, partnering to develop weight management strategies that prioritize affordability, accessibility, and personalization. Our focus includes oversight of GLP-1 utilization and outcomes to ensure clinically appropriate use and long-term value.

Furthermore, Prime is continuing to refine and develop additional programs through KeepWell™ to mitigate the increasing pharmacy spend and utilization trends of these high-profile products. Visit our GLP-1 strategy page to explore how we support tailored solutions that improve member health and manage costs.

Questions?

Reach out to your account team representative.